Novel Treatment Strategy Using Trafermin® Consisting of bFGF for Intractable Pancreatic Fistula-A Case Report

Pancreatic fistula is one of the most critical complication following distal pancreatectomy. We report here a successfully treated case with intractable pancreatic fistula using Trafermin® consisting of basic fibroblast growth factor(bFGF). A 60- year-old man underwent laparoscopic distal pancreatec...

Full description

Saved in:

Bibliographic Details
Published in:	Gan to kagaku ryoho Vol. 49; no. 3; p. 342
Main Authors:	Kawamura, Taiyo, Shimomura, Katsumi, Taniguchi, Fumihiro, Komatsu, Shuhei, Shibata, Rie, Konishi, Tomoki, Matsubara, Daiki, Soga, Koji, Ikeda, Jun, Shioaki, Yasuhiro
Format:	Journal Article
Language:	Japanese
Published:	Japan 01-03-2022
Subjects:	Fibroblast Growth Factor 2 - therapeutic use Fibroblast Growth Factors - therapeutic use Humans Male Middle Aged Pancreatectomy - adverse effects Pancreatic Fistula - drug therapy Pancreatic Fistula - etiology Peptide Fragments - therapeutic use Postoperative Complications - drug therapy Postoperative Complications - etiology
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Pancreatic fistula is one of the most critical complication following distal pancreatectomy. We report here a successfully treated case with intractable pancreatic fistula using Trafermin® consisting of basic fibroblast growth factor(bFGF). A 60- year-old man underwent laparoscopic distal pancreatectomy. After surgery, pancreatic fistula was occurred. Pancreatic fistula persisted for 3 months despite of several conservative treatments. After obtaining informed consent, we started to inject 50μg/day of Trafermin® through a drainage tube into the dehiscence of pancreas. Consequently, pancreatic fistula was successfully closed within a week. This technique could be one of the treatment choices for intractable pancreatic fistula following distal pancreatectomy.
ISSN:	0385-0684